SCHEMBL3385956

SCHEMBL3385956

CC(C)(C)OC(=O)N1CCSC1C(=O)NC(CCO)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 1/20 0.39
HTRA1 Q92743 1/20 0.38
CCR5 P51681 3/20 0.37
ATM Q13315 1/20 0.37
RIPK1 Q13546 2/20 0.37
KIT P10721 1/20 0.37
TACR1 P25103 3/20 0.36
STS P08842 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
PRKACA P17612 1/20 0.35
CDK8 P49336 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
PRKX P51817 1/20 0.35
PRKCQ Q04759 1/20 0.35
ROCK1 Q13464 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386859 1.00 PTGFR (0.39) PTGFRHTRA1CCR5ATMRIPK1
SCHEMBL13004626 1.00 PTGFR (0.39) PTGFRHTRA1CCR5ATMRIPK1
SCHEMBL3382903 0.92 RIPK1 (0.46) PTGFRHTRA1ATMRIPK1STS
SCHEMBL13715039 0.90 PTGFR (0.43) PTGFRCCR5ATMKITTACR1
SCHEMBL18055685 0.90 PTGFR (0.43) PTGFRCCR5ATMKITTACR1
SCHEMBL3384021 0.87 ATM (0.39) PTGFRCCR5ATMSTSKDM4E
SCHEMBL13005180 0.86 GPR119 (0.38) PTGFRHTRA1
SCHEMBL7045396 0.85 PRKACA (0.40) PTGFRCCR5PRKACACDK8GSK3A
SCHEMBL3383580 0.85 PRKACA (0.40) PTGFRCCR5PRKACACDK8GSK3A
SCHEMBL13005178 0.82 KDM4D (0.37) PTGFRTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415480-B2 Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor MERCK SERONO SA (CH) 2013-04-09 US disclosed
EP-1487442-B1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR MERCK SERONO SA (CH) 2010-12-01 EP disclosed
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2009-08-27 US disclosed
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR LABORATOIRES SERONO S.A. (CH) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215749-A9 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HTRA1 307/4885CCR5 1468/4885
US-20080255094-A1 THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR PTGER4, PTGER2, PTGER1 PTGFR 9/4885HTRA1 307/4885CCR5 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.